461 related articles for article (PubMed ID: 23306365)
1. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
2. Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli.
Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Mol Immunol; 2013 May; 54(1):32-9. PubMed ID: 23220068
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
4. In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections.
Savar NS; Jahanian-Najafabadi A; Mahdavi M; Shokrgozar MA; Jafari A; Bouzari S
J Biotechnol; 2014 Apr; 175():31-7. PubMed ID: 24530504
[TBL] [Abstract][Full Text] [Related]
5. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
6. Dimeric and Trimeric Fusion Proteins Generated with Fimbrial Adhesins of Uropathogenic
Luna-Pineda VM; Reyes-Grajeda JP; Cruz-Córdova A; Saldaña-Ahuactzi Z; Ochoa SA; Maldonado-Bernal C; Cázares-Domínguez V; Moreno-Fierros L; Arellano-Galindo J; Hernández-Castro R; Xicohtencatl-Cortes J
Front Cell Infect Microbiol; 2016; 6():135. PubMed ID: 27843814
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
[TBL] [Abstract][Full Text] [Related]
8. Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic Escherichia coli antigens.
Asadi Karam MR; Habibi M; Bouzari S
Biologicals; 2016 Sep; 44(5):378-86. PubMed ID: 27461240
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
10. Construction and development of FimH lectin domain for rising immune response after injection by uropathogenic E. coli.
Zandi M; Fallah Mehrabadi J; Mahdavi M; Irani S
Hum Antibodies; 2020; 28(2):169-178. PubMed ID: 32116244
[TBL] [Abstract][Full Text] [Related]
11. Rapid Bladder Interleukin-10 Synthesis in Response to Uropathogenic Escherichia coli Is Part of a Defense Strategy Triggered by the Major Bacterial Flagellar Filament FliC and Contingent on TLR5.
Acharya D; Sullivan MJ; Duell BL; Goh KGK; Katupitiya L; Gosling D; Chamoun MN; Kakkanat A; Chattopadhyay D; Crowley M; Crossman DK; Schembri MA; Ulett GC
mSphere; 2019 Nov; 4(6):. PubMed ID: 31776239
[TBL] [Abstract][Full Text] [Related]
12. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted immune responses and protective efficacy elicited by a recombinant autolyzed Salmonella expressing FliC flagellar antigen of F18
Won G; Lee JH
Vaccine; 2016 Dec; 34(50):6335-6342. PubMed ID: 27817960
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
15. Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli.
Wen LJ; Hou XL; Wang GH; Yu LY; Wei XM; Liu JK; Liu Q; Wei CH
Vaccine; 2012 May; 30(22):3339-49. PubMed ID: 21856357
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.
Poggio TV; La Torre JL; Scodeller EA
Can J Microbiol; 2006 Nov; 52(11):1093-102. PubMed ID: 17215901
[TBL] [Abstract][Full Text] [Related]
17. Immunization with recombinant protein Ag43::UpaH with alum and 1,25(OH)2D3 adjuvants significantly protects Balb/C mice against urinary tract infection caused by uropathogenic Escherichia coli.
Habibi M; Azimi S; Khoobbakht D; Roghanian P; Asadi Karam MR
Int Immunopharmacol; 2021 Jul; 96():107638. PubMed ID: 33848909
[TBL] [Abstract][Full Text] [Related]
18. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice.
Lin R; Zhu B; Zhang Y; Bai Y; Zhi F; Long B; Li Y; Wu Y; Wu X; Fan H
Microb Pathog; 2017 Apr; 105():19-24. PubMed ID: 28163157
[TBL] [Abstract][Full Text] [Related]
20. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
